UY35596A - Compuestos para la modulación de quinasas, y sus indicaciones - Google Patents
Compuestos para la modulación de quinasas, y sus indicacionesInfo
- Publication number
- UY35596A UY35596A UY0001035596A UY35596A UY35596A UY 35596 A UY35596 A UY 35596A UY 0001035596 A UY0001035596 A UY 0001035596A UY 35596 A UY35596 A UY 35596A UY 35596 A UY35596 A UY 35596A
- Authority
- UY
- Uruguay
- Prior art keywords
- compounds
- kinases
- indications
- modulation
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361829190P | 2013-05-30 | 2013-05-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY35596A true UY35596A (es) | 2014-12-31 |
Family
ID=51023140
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001035596A UY35596A (es) | 2013-05-30 | 2014-05-30 | Compuestos para la modulación de quinasas, y sus indicaciones |
Country Status (18)
Families Citing this family (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
| CN101808994B (zh) | 2007-07-17 | 2013-05-15 | 普莱希科公司 | 用于激酶调节的化合物和方法以及其适应症 |
| WO2009143018A2 (en) | 2008-05-19 | 2009-11-26 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| MY156210A (en) | 2009-11-18 | 2016-01-29 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| BR112012015745A2 (pt) | 2009-12-23 | 2016-05-17 | Plexxikon Inc | compostos e métodos para a modulação de quinase, e indicações dos mesmos |
| TWI510487B (zh) | 2010-04-21 | 2015-12-01 | Plexxikon Inc | 用於激酶調節的化合物和方法及其適應症 |
| AU2012214762B2 (en) | 2011-02-07 | 2015-08-13 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| BR112013029163A2 (pt) | 2011-05-17 | 2017-01-31 | Plexxikon Inc | modulação quinase e indicações dos mesmos |
| US9358235B2 (en) | 2012-03-19 | 2016-06-07 | Plexxikon Inc. | Kinase modulation, and indications therefor |
| CN106279202A (zh) * | 2012-05-03 | 2017-01-04 | 霍夫曼-拉罗奇有限公司 | 作为lrrk2调节剂用于治疗帕金森病的吡唑氨基嘧啶衍生物 |
| US9150570B2 (en) * | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
| JP6318156B2 (ja) | 2012-09-06 | 2018-04-25 | プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． | キナーゼをモジュレートするための化合物および方法、ならびにその指標 |
| US9676748B2 (en) | 2012-12-21 | 2017-06-13 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| JP6325078B2 (ja) | 2013-03-15 | 2018-05-16 | プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． | ヘテロ環式化合物およびその使用 |
| US20140303121A1 (en) | 2013-03-15 | 2014-10-09 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
| EP3004060B1 (en) | 2013-05-30 | 2019-11-27 | Plexxikon Inc. | Compounds for kinase modulation, and indications therefor |
| WO2015134536A1 (en) | 2014-03-04 | 2015-09-11 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| JP6832846B2 (ja) | 2014-09-15 | 2021-02-24 | プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． | ヘテロ環化合物およびその用途 |
| EA037112B1 (ru) * | 2015-03-02 | 2021-02-08 | Ригель Фармасьютикалс, Инк. | Ингибиторы tgf- |
| US10160755B2 (en) | 2015-04-08 | 2018-12-25 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| CN104829613B (zh) * | 2015-04-13 | 2020-06-09 | 赤峰蒙广生物科技有限公司 | 二芳基取代的吡唑并环类衍生物、其制备方法及其在医药领域的应用 |
| MX2017013975A (es) | 2015-05-06 | 2018-01-16 | Plexxikon Inc | Formas solidas de quinasas que modulan un compuesto. |
| US9745298B2 (en) | 2015-05-06 | 2017-08-29 | Plexxikon Inc. | Synthesis of a compound that modulates kinases |
| CA2986735A1 (en) * | 2015-05-22 | 2016-12-01 | Plexxikon Inc. | Solid forms of a compound for modulating kinases |
| WO2016191296A1 (en) * | 2015-05-22 | 2016-12-01 | Plexxikon Inc. | Plx-8394 or plx-7904 for use in the treatment of braf-v600-related diseases |
| SI3322706T1 (sl) | 2015-07-16 | 2021-04-30 | Array Biopharma, Inc. | Substituirane pirazolo(1,5-A)piridinske spojine kot zaviralci ret-kinaze |
| WO2017019804A2 (en) | 2015-07-28 | 2017-02-02 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| CN113754656A (zh) | 2015-09-21 | 2021-12-07 | 普莱希科公司 | 杂环化合物及其应用 |
| AU2016344058A1 (en) | 2015-10-26 | 2018-05-17 | Array Biopharma Inc. | Point mutations in Trk inhibitor-resistant cancer and methods relating to the same |
| BR112018011475A2 (pt) | 2015-12-07 | 2018-12-04 | Plexxikon Inc | compostos e métodos para modulação de quinase e indicação para a mesma |
| US9630968B1 (en) | 2015-12-23 | 2017-04-25 | Arqule, Inc. | Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof |
| US10160747B2 (en) | 2016-03-16 | 2018-12-25 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| BR112018070017A2 (pt) | 2016-04-04 | 2019-02-05 | Loxo Oncology Inc | métodos de tratamento de cânceres pediátricos |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| TN2018000335A1 (en) | 2016-04-04 | 2020-01-16 | Loxo Oncology Inc | Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
| PL3800189T3 (pl) | 2016-05-18 | 2023-10-23 | Loxo Oncology, Inc. | Wytwarzanie (s)-n-(5-((r)-2-(2,5-difluorofenylo)pirolidyn-1-ylo)pirazolo[1,5-a]pirymidyn-3-ylo)-3-hydroksypirolidyno-1-karboksyamidu |
| EP3472165B1 (en) * | 2016-06-21 | 2023-09-06 | Nerviano Medical Sciences S.r.l. | N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors |
| CN107722013B (zh) * | 2016-08-11 | 2021-01-12 | 中国科学院上海药物研究所 | 去氮嘌呤类化合物及其药物组合物、制备方法和用途 |
| MX2019002212A (es) * | 2016-08-24 | 2019-07-08 | Arqule Inc | Compuestos de amino-pirrolo-pirimidinona y metodos de uso de los mismos. |
| TW201815766A (zh) | 2016-09-22 | 2018-05-01 | 美商普雷辛肯公司 | 用於ｉｄｏ及ｔｄｏ調節之化合物及方法以及其適應症 |
| JP2019532944A (ja) | 2016-09-23 | 2019-11-14 | セルイプセ | Ｌｉｍｋ介在性疾患における、ｌｉｍキナーゼ阻害剤、医薬組成物および使用方法 |
| TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| AU2017395023B2 (en) | 2016-12-23 | 2022-04-07 | Plexxikon Inc. | Compounds and methods for CDK8 modulation and indications therefor |
| AU2018209164B2 (en) | 2017-01-17 | 2021-11-04 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
| ES2948194T3 (es) | 2017-01-18 | 2023-09-01 | Array Biopharma Inc | Compuestos de pirazolo[1,5-a]pirazina sustituida como inhibidores de la cinasa RET |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| AU2018237047A1 (en) | 2017-03-20 | 2019-10-17 | Plexxikon Inc. | Crystalline forms of 4-(1-(1,1-di(pyridin-2-yl)ethyl)-6-(3,5-dimethylisoxazol-4-yl)-1H- pyrrolo[3,2-b]pyridin-3-yl)benzoic acid that inhibits bromodomain |
| WO2018226846A1 (en) | 2017-06-07 | 2018-12-13 | Plexxikon Inc. | Compounds and methods for kinase modulation |
| TWI805599B (zh) | 2017-07-25 | 2023-06-21 | 美商第一三共公司 | 激酶調節化合物之調配物 |
| KR102328351B1 (ko) * | 2017-07-29 | 2021-11-19 | 루트리스 파마 엘티디. | 신규한 BRaf 억제제 및 피부 반응의 치료를 위한 이의 용도 |
| TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
| TWI812649B (zh) | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
| EP3694855A1 (en) | 2017-10-13 | 2020-08-19 | Plexxikon Inc. | Solid forms of a compound for modulating kinases |
| CN112165958A (zh) | 2017-10-27 | 2021-01-01 | 普莱希科公司 | 调制激酶的化合物的制剂 |
| CN111971286B (zh) | 2018-01-18 | 2023-04-14 | 阿雷生物药品公司 | 作为RET激酶抑制剂的取代的吡咯并[2,3-d]嘧啶化合物 |
| WO2019143994A1 (en) | 2018-01-18 | 2019-07-25 | Array Biopharma Inc. | Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors |
| CN111630054B (zh) | 2018-01-18 | 2023-05-09 | 奥瑞生物药品公司 | 作为RET激酶抑制剂的取代的吡唑并[3,4-d]嘧啶化合物 |
| WO2019142128A1 (en) * | 2018-01-18 | 2019-07-25 | Integral Biosciences Private Limited | Dual inhibitors of alk5 and p38α map kinase |
| CA3089678A1 (en) | 2018-01-31 | 2019-08-08 | Heparegenix Gmbh | Protein kinase mkk4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| CN112119072A (zh) | 2018-03-20 | 2020-12-22 | 普莱希科公司 | 用于ido和tdo调节的化合物和方法，以及其适应症 |
| US11731968B2 (en) | 2018-06-21 | 2023-08-22 | Heparegenix Gmbh | Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| WO2020016243A1 (en) | 2018-07-16 | 2020-01-23 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| CN117285467A (zh) | 2018-07-31 | 2023-12-26 | 罗索肿瘤学公司 | 喷雾干燥的分散体和制剂 |
| AU2019324089B2 (en) | 2018-08-21 | 2024-06-13 | Kyorin Pharmaceutical Co., Ltd. | Bicyclic heteroaromatic ring derivative |
| US11964988B2 (en) | 2018-09-10 | 2024-04-23 | Array Biopharma Inc. | Fused heterocyclic compounds as RET kinase inhibitors |
| PL3891142T3 (pl) * | 2018-12-03 | 2023-01-02 | Boehringer Ingelheim International Gmbh | Związki heteroaromatyczne jako inhibitory waniny |
| WO2020124397A1 (en) * | 2018-12-19 | 2020-06-25 | Inventisbio Shanghai Ltd. | C-terminal src kinase inhibitors |
| WO2020131674A1 (en) | 2018-12-19 | 2020-06-25 | Array Biopharma Inc. | 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer |
| US20220081438A1 (en) | 2018-12-19 | 2022-03-17 | Array Biopharma Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases |
| CN113710668A (zh) | 2019-04-09 | 2021-11-26 | 普莱希科公司 | 用于ep300或cbp调节及其适应症的缩合吖嗪 |
| EP3976607A4 (en) * | 2019-05-31 | 2023-07-19 | Fochon Biosciences, Ltd. | SUBSTITUTED PYRROLO[2,3-B]PYRIDINE AND PYRAZOLO[3,4-B]PYRIDINE DERIVATIVES AS PROTEIN KINAS INHIBITORS |
| JP2022540200A (ja) | 2019-07-11 | 2022-09-14 | エスケイプ・バイオ・インコーポレイテッド | Ｌｒｒｋ２阻害剤としてのインダゾールおよびアザインダゾール |
| KR20220046584A (ko) | 2019-07-29 | 2022-04-14 | 헤파레게닉스 게엠베하 | 간 재생 촉진 또는 간세포 사멸 감소 또는 예방을 위한 헤테로아릴-치환된 피라졸로-피리딘 단백질 키나제 억제제 |
| US20230101747A1 (en) | 2019-12-06 | 2023-03-30 | Schrödinger, Inc. | Cyclic compounds and methods of using same |
| EP4081526A1 (en) | 2019-12-27 | 2022-11-02 | Schrödinger, Inc. | Cyclic compounds and methods of using same |
| CN114981267A (zh) | 2020-01-15 | 2022-08-30 | 海帕瑞吉尼克斯股份有限公司 | 用于治疗肝脏疾病的mkk4抑制剂3-苯甲酰基-1h-吡咯并[2,3-b]吡啶衍生物 |
| US11807626B2 (en) | 2020-04-23 | 2023-11-07 | Opna Bio SA | Compounds and methods for CD73 modulation and indications therefor |
| EP4196228A1 (en) * | 2020-08-13 | 2023-06-21 | Albert Einstein College of Medicine | N-cyclyl-sulfonamides useful for inhibiting raf |
| CN116322690A (zh) | 2020-08-21 | 2023-06-23 | 奥普纳生物有限公司 | 组合的药物抗癌疗法 |
| US20230365584A1 (en) | 2020-09-10 | 2023-11-16 | Schrödinger, Inc. | Heterocyclic pericondensed cdc7 kinase inhibitors for the treatment of cancer |
| US20240148732A1 (en) | 2021-01-26 | 2024-05-09 | Schrödinger, Inc. | Tricyclic compounds useful in the treatment of cancer, autoimmune and inflammatory disorders |
| CN113018415B (zh) * | 2021-03-17 | 2022-07-01 | 遵义医科大学 | 一种药物组合及其应用 |
| TW202300150A (zh) | 2021-03-18 | 2023-01-01 | 美商薛定諤公司 | 環狀化合物及其使用方法 |
| BR112023025757A2 (pt) * | 2021-06-09 | 2024-02-27 | Hoffmann La Roche | Formas sólidas de um composto de fórmula, composição farmacêutica, uso de forma sólida, método para tratamento terapêutico, processos para a preparação de um composto de fórmula e para a preparação de forma a polimórfica cristalina de um composto de fórmula e invenção |
| CN113941001B (zh) * | 2021-12-09 | 2023-09-08 | 宁夏医科大学 | Craf抑制剂在制备抗肿瘤的药物中的应用 |
| WO2023213965A1 (en) * | 2022-05-05 | 2023-11-09 | University Of Dundee | Inhibitors of cdk8 and cdk19 |
| WO2023240024A1 (en) * | 2022-06-08 | 2023-12-14 | Nikang Therapeutics, Inc. | Sulfamide derivatives as cyclin-dependent kinase 2 inhibitors |
Family Cites Families (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040171062A1 (en) | 2002-02-28 | 2004-09-02 | Plexxikon, Inc. | Methods for the design of molecular scaffolds and ligands |
| MXPA05002444A (es) | 2002-09-06 | 2005-09-30 | Insert Therapeutics Inc | Polimeros a base de ciclodextrina para el suministro de agentes terapeuticos. |
| CA2503905A1 (en) | 2002-09-16 | 2004-03-25 | Plexxikon, Inc. | Crystal structure of pim-1 kinase |
| US20050048573A1 (en) | 2003-02-03 | 2005-03-03 | Plexxikon, Inc. | PDE5A crystal structure and uses |
| JP2007524374A (ja) | 2003-02-28 | 2007-08-30 | プレキシコン，インコーポレーテッド | Ｐｙｋ２結晶構造および使用 |
| US20050079548A1 (en) | 2003-07-07 | 2005-04-14 | Plexxikon, Inc. | Ligand development using PDE4B crystal structures |
| US7348338B2 (en) | 2003-07-17 | 2008-03-25 | Plexxikon, Inc. | PPAR active compounds |
| WO2005009958A1 (en) | 2003-07-17 | 2005-02-03 | Plexxikon, Inc. | Ppar active compounds |
| US20050164300A1 (en) | 2003-09-15 | 2005-07-28 | Plexxikon, Inc. | Molecular scaffolds for kinase ligand development |
| US20070066641A1 (en) | 2003-12-19 | 2007-03-22 | Prabha Ibrahim | Compounds and methods for development of RET modulators |
| US7504509B2 (en) | 2003-12-19 | 2009-03-17 | Plexxikon, Inc. | Compounds and methods for development of Ret modulators |
| US7517970B2 (en) | 2003-12-19 | 2009-04-14 | Plexxikon, Inc. | Nucleic acids encoding kinase and phosphatase enzymes, expression vectors and cells containing same |
| CN101031293A (zh) | 2004-05-06 | 2007-09-05 | 普莱希科公司 | Pde4b抑制剂及其应用 |
| WO2006009755A2 (en) | 2004-06-17 | 2006-01-26 | Plexxikon, Inc. | Azaindoles modulating c-kit activity and uses therefor |
| US7498342B2 (en) | 2004-06-17 | 2009-03-03 | Plexxikon, Inc. | Compounds modulating c-kit activity |
| CN101048407A (zh) | 2004-09-03 | 2007-10-03 | 普莱希科公司 | 双环杂芳基pde4b抑制剂 |
| US20060135540A1 (en) | 2004-11-30 | 2006-06-22 | Jack Lin | PPAR active compounds |
| CA2588953A1 (en) | 2004-11-30 | 2006-06-08 | Plexxikon, Inc. | Ppar active compounds |
| US20060160135A1 (en) | 2004-12-08 | 2006-07-20 | Weiru Wang | SF-1 and LRH-1 modulator development |
| EP1885723A2 (en) | 2005-05-17 | 2008-02-13 | Plexxikon, Inc. | Pyrrolo[2,3-b]pyridine derivatives as protein kinase inhibitors |
| WO2007002433A1 (en) | 2005-06-22 | 2007-01-04 | Plexxikon, Inc. | Pyrrolo [2, 3-b] pyridine derivatives as protein kinase inhibitors |
| TW200800872A (en) | 2005-09-07 | 2008-01-01 | Plexxikon Inc | PPAR active compounds |
| CA2621275A1 (en) | 2005-09-07 | 2007-03-15 | Plexxikon, Inc. | 1 , 4 and 1 , 5-disubstituted indole derivatives for use as ppar active compounds |
| JP2009507079A (ja) | 2005-09-07 | 2009-02-19 | プレキシコン，インコーポレーテッド | Ｐｐａｒ活性化合物 |
| WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
| EP2094701A2 (en) | 2006-12-21 | 2009-09-02 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
| WO2008079909A1 (en) | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Pyrrolo [2,3-b] pyridines as kinase modulators |
| PE20121126A1 (es) | 2006-12-21 | 2012-08-24 | Plexxikon Inc | Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa |
| PE20090159A1 (es) | 2007-03-08 | 2009-02-21 | Plexxikon Inc | COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs |
| AU2008222807A1 (en) | 2007-03-08 | 2008-09-12 | Plexxikon, Inc. | PPAR active compounds |
| CN101808994B (zh) | 2007-07-17 | 2013-05-15 | 普莱希科公司 | 用于激酶调节的化合物和方法以及其适应症 |
| JP2011513330A (ja) | 2008-02-29 | 2011-04-28 | アレイ バイオファーマ、インコーポレイテッド | Ｒａｆ阻害化合物およびその使用方法 |
| BRPI0908268A2 (pt) * | 2008-02-29 | 2018-10-30 | Array Biopharma Inc | compostos do inibidor de raf e seus métodos de uso |
| UA103319C2 (en) * | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
| WO2009143018A2 (en) | 2008-05-19 | 2009-11-26 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
| PE20091846A1 (es) * | 2008-05-19 | 2009-12-16 | Plexxikon Inc | DERIVADOS DE PIRROLO[2,3-d]-PIRIMIDINA COMO MODULADORES DE CINASAS |
| AU2009257635A1 (en) | 2008-06-10 | 2009-12-17 | Plexxikon, Inc. | 5H-Pyrrolo [2,3-b] pyrazine derivatives for kinase modulation, and indications therefor |
| US8110576B2 (en) | 2008-06-10 | 2012-02-07 | Plexxikon Inc. | Substituted pyrrolo[2,3b]pyrazines and methods for treatment of raf protein kinase-mediated indications |
| EP2406259A1 (en) * | 2009-03-11 | 2012-01-18 | Plexxikon, Inc. | Pyrrolo [2, 3-b]pyridine derivatives for the inhibition of raf kinases |
| CN102421775A (zh) | 2009-03-11 | 2012-04-18 | 普莱希科公司 | 抑制Raf激酶的吡咯并[2，3-b]吡啶衍生物 |
| WO2010111527A1 (en) | 2009-03-26 | 2010-09-30 | Plexxikon, Inc. | Pyrazolo [ 3, 4 -b] pyridines as kinase inhibitors and their medical use |
| US9447089B2 (en) | 2009-04-03 | 2016-09-20 | Plexxikon Inc. | Compositions and uses thereof |
| SG175877A1 (en) | 2009-05-04 | 2011-12-29 | Plexxikon Inc | Compounds and methods for inhibition of renin, and indications therefor |
| TW201041888A (en) | 2009-05-06 | 2010-12-01 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| AR077975A1 (es) * | 2009-08-28 | 2011-10-05 | Irm Llc | Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina |
| CN102482283A (zh) | 2009-08-28 | 2012-05-30 | 阵列生物制药公司 | Raf抑制剂化合物及其使用方法 |
| SG178534A1 (en) | 2009-08-28 | 2012-03-29 | Array Biopharma Inc | Raf inhibitor compounds and methods of use thereof |
| SG178899A1 (en) * | 2009-08-28 | 2012-04-27 | Array Biopharma Inc | Raf inhibitor compounds and methods of use thereof |
| US8242260B2 (en) * | 2009-08-28 | 2012-08-14 | Novartis Ag | Compounds and compositions as protein kinase inhibitors |
| UA105813C2 (uk) | 2009-11-06 | 2014-06-25 | Плексікон, Інк. | Сполуки-інгібітори кіназ та фармацевтична композиція (варіанти) |
| WO2011059610A1 (en) * | 2009-11-10 | 2011-05-19 | Glaxosmithkline Llc | Benzene sulfonamide thiazole and oxazole compounds |
| MY156210A (en) | 2009-11-18 | 2016-01-29 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| BR112012015745A2 (pt) | 2009-12-23 | 2016-05-17 | Plexxikon Inc | compostos e métodos para a modulação de quinase, e indicações dos mesmos |
| TWI510487B (zh) | 2010-04-21 | 2015-12-01 | Plexxikon Inc | 用於激酶調節的化合物和方法及其適應症 |
| US8642606B2 (en) | 2010-09-29 | 2014-02-04 | Plexxikon Inc. | ZAP-70 active compounds |
| AU2012214762B2 (en) | 2011-02-07 | 2015-08-13 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| TWI558702B (zh) | 2011-02-21 | 2016-11-21 | 普雷辛肯公司 | 醫藥活性物質的固態形式 |
| BR112013029163A2 (pt) | 2011-05-17 | 2017-01-31 | Plexxikon Inc | modulação quinase e indicações dos mesmos |
| WO2013043935A1 (en) * | 2011-09-21 | 2013-03-28 | Neupharma, Inc. | Certain chemical entites, compositions, and methods |
| US9358235B2 (en) | 2012-03-19 | 2016-06-07 | Plexxikon Inc. | Kinase modulation, and indications therefor |
| US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
| JP6318156B2 (ja) * | 2012-09-06 | 2018-04-25 | プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． | キナーゼをモジュレートするための化合物および方法、ならびにその指標 |
| US9676748B2 (en) | 2012-12-21 | 2017-06-13 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| JP6325078B2 (ja) | 2013-03-15 | 2018-05-16 | プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． | ヘテロ環式化合物およびその使用 |
| US20140303121A1 (en) | 2013-03-15 | 2014-10-09 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
| EP3004060B1 (en) | 2013-05-30 | 2019-11-27 | Plexxikon Inc. | Compounds for kinase modulation, and indications therefor |
| WO2015134536A1 (en) | 2014-03-04 | 2015-09-11 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| JP6832846B2 (ja) | 2014-09-15 | 2021-02-24 | プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． | ヘテロ環化合物およびその用途 |
| US10160755B2 (en) | 2015-04-08 | 2018-12-25 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| US9745298B2 (en) | 2015-05-06 | 2017-08-29 | Plexxikon Inc. | Synthesis of a compound that modulates kinases |
| MX2017013975A (es) | 2015-05-06 | 2018-01-16 | Plexxikon Inc | Formas solidas de quinasas que modulan un compuesto. |
| WO2016191296A1 (en) | 2015-05-22 | 2016-12-01 | Plexxikon Inc. | Plx-8394 or plx-7904 for use in the treatment of braf-v600-related diseases |
| CA2986735A1 (en) | 2015-05-22 | 2016-12-01 | Plexxikon Inc. | Solid forms of a compound for modulating kinases |
| WO2017019804A2 (en) | 2015-07-28 | 2017-02-02 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| CN113754656A (zh) | 2015-09-21 | 2021-12-07 | 普莱希科公司 | 杂环化合物及其应用 |
| BR112018011475A2 (pt) | 2015-12-07 | 2018-12-04 | Plexxikon Inc | compostos e métodos para modulação de quinase e indicação para a mesma |
| US10160747B2 (en) | 2016-03-16 | 2018-12-25 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| TW201815766A (zh) | 2016-09-22 | 2018-05-01 | 美商普雷辛肯公司 | 用於ｉｄｏ及ｔｄｏ調節之化合物及方法以及其適應症 |
| AU2017395023B2 (en) | 2016-12-23 | 2022-04-07 | Plexxikon Inc. | Compounds and methods for CDK8 modulation and indications therefor |
| AU2018237047A1 (en) | 2017-03-20 | 2019-10-17 | Plexxikon Inc. | Crystalline forms of 4-(1-(1,1-di(pyridin-2-yl)ethyl)-6-(3,5-dimethylisoxazol-4-yl)-1H- pyrrolo[3,2-b]pyridin-3-yl)benzoic acid that inhibits bromodomain |
| WO2018226846A1 (en) | 2017-06-07 | 2018-12-13 | Plexxikon Inc. | Compounds and methods for kinase modulation |
-
2014
- 2014-05-29 EP EP14733877.6A patent/EP3004060B1/en active Active
- 2014-05-29 US US14/290,786 patent/US9873700B2/en active Active
- 2014-05-29 TW TW103118934A patent/TW201533028A/zh unknown
- 2014-05-29 BR BR112015028845A patent/BR112015028845A2/pt not_active IP Right Cessation
- 2014-05-29 CN CN201480029525.6A patent/CN105228983A/zh active Pending
- 2014-05-29 RU RU2015149937A patent/RU2015149937A/ru unknown
- 2014-05-29 CA CA2912568A patent/CA2912568A1/en not_active Abandoned
- 2014-05-29 JP JP2016516830A patent/JP2016520131A/ja active Pending
- 2014-05-29 MX MX2015015966A patent/MX2015015966A/es unknown
- 2014-05-29 KR KR1020157033201A patent/KR20160013028A/ko not_active Application Discontinuation
- 2014-05-29 AU AU2014274093A patent/AU2014274093B2/en not_active Ceased
- 2014-05-29 WO PCT/US2014/040076 patent/WO2014194127A1/en active Application Filing
- 2014-05-29 SG SG11201509338QA patent/SG11201509338QA/en unknown
- 2014-05-30 UY UY0001035596A patent/UY35596A/es not_active Application Discontinuation
- 2014-05-30 AR ARP140102152A patent/AR096450A1/es unknown
-
2015
- 2015-11-12 IL IL242587A patent/IL242587A0/en unknown
- 2015-11-23 PH PH12015502610A patent/PH12015502610A1/en unknown
-
2016
- 2016-07-04 HK HK16107741.9A patent/HK1219732A1/zh unknown
-
2017
- 2017-12-11 US US15/838,268 patent/US10421761B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2014274093A1 (en) | 2015-12-03 |
| IL242587A0 (en) | 2016-02-01 |
| EP3004060A1 (en) | 2016-04-13 |
| JP2016520131A (ja) | 2016-07-11 |
| US9873700B2 (en) | 2018-01-23 |
| BR112015028845A2 (pt) | 2017-07-25 |
| AU2014274093B2 (en) | 2018-11-08 |
| CA2912568A1 (en) | 2014-12-04 |
| US20180099975A1 (en) | 2018-04-12 |
| EP3004060B1 (en) | 2019-11-27 |
| US20140357612A1 (en) | 2014-12-04 |
| HK1219732A1 (zh) | 2017-04-13 |
| AR096450A1 (es) | 2015-12-30 |
| CN105228983A (zh) | 2016-01-06 |
| KR20160013028A (ko) | 2016-02-03 |
| WO2014194127A1 (en) | 2014-12-04 |
| RU2015149937A (ru) | 2017-07-06 |
| US10421761B2 (en) | 2019-09-24 |
| SG11201509338QA (en) | 2015-12-30 |
| MX2015015966A (es) | 2016-04-13 |
| PH12015502610A1 (en) | 2016-02-29 |
| TW201533028A (zh) | 2015-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY35596A (es) | Compuestos para la modulación de quinasas, y sus indicaciones | |
| UY35240A (es) | Compuestos y métodos para la modulación de quinasas y sus indicaciones | |
| ECSP13012869A (es) | Compuestos y métodos para la modulación de quinasas e indicaciones para los mismos | |
| UY35798A (es) | Inhibidores del receptor del factor de crecimiento de fibroblastos | |
| PH12016500582A1 (en) | Heterocyclic compounds and uses thereof | |
| ECSP14013153A (es) | Compuestos inhibidores de metaloenzimas | |
| UY35464A (es) | Inhibidores covalentes de kras g12c. | |
| ECSP14033037A (es) | Síntesis de compuestos heterocíclicos | |
| ECSP14013159A (es) | Compuestos inhibidores de metaloenzimas | |
| ECSP099444A (es) | Compuestos y métodos para modulación de cinasas, e indicaciones para ello | |
| ECSP12011720A (es) | Compuestos heterocíclicos y usos de los mismos | |
| GT201400034A (es) | Compuestos y composiciones como inhibidores de la quinasa c-kit | |
| UY34541A (es) | ?derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina?. | |
| UY34725A (es) | Nuevos derivados de tienopirimidina, procesos para su preparación y sus usos terapéuticos. | |
| UY35274A (es) | Compuestos y métodos para tratar infecciones bacterianas | |
| NI201600070A (es) | Inhibidores tetracíclicos de autotaxina | |
| CO2017005732A2 (es) | Compuestos de dihidropirimidin-2-ona y sus usos médicos | |
| UY33976A (es) | Derivados de pirazolo-pirimidina. | |
| DK3189844T3 (da) | Pluripotent stamcelle til behandling af diabetisk hudsår | |
| BR112018008931A8 (pt) | ?compostos para tratamento de distúrbios hipoproliferativos? | |
| UY34807A (es) | Derivados monocíclicos de heteroarilcicloalquil- diamina | |
| UY34755A (es) | Agentes para el control de la glycaspis brimblecombei | |
| EA201690709A1 (ru) | Применение одипарцила в лечении мукополисахаридоза | |
| ECSP13012484A (es) | Nuevos moduladores de trpv3 | |
| TWD180406S (zh) | 拋棄式尿布 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20211206 |